Last Updated : April 26, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Zejula | Niraparib | Ovarian Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xtandi | Enzalutamide | mHSPC | Reimburse with clinical criteria and/or conditions | Complete | ||
| Soliris | eculizumab | Neuromyelitis optica spectrum disorder | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ultomiris | ravulizumab | Neuromyelitis optica spectrum disorder (NMOSD) | Reimburse with clinical criteria and/or conditions | Active | ||
| N/A | panitumumab | Left-sided metastatic colorectal cancer (mCRC) | Reimburse with clinical criteria and/or conditions | Active | ||
| Adcetris | Brentuximab Vedotin | Primary cutaneous anaplastic large cell Lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Forxiga | dapagliflozin | Heart failure with reduced ejection fraction | Reimburse with clinical criteria and/or conditions | Complete | ||
| Adcetris | Brentuximab Vedotin | Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Calquence | Acalabrutinib | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Calquence | Acalabrutinib | Chronic Lymphocytic Leukemia (CLL) | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 26, 2024